STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National...
Hence then, the article about leqembi approved for iv maintenance treatment in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Leqembi® approved for IV maintenance treatment in China )
Also on site :
- Popular Toddler Snacks Sold at Costco, Target and Walmart Recalled Over Potentially Deadly Choking Hazard
- Kraft Mac & Cheese Just Launched 2 Unexpected New Flavors—and One Is Inspired by a Beloved Breakfast Treat
- Grand Circle Cruise Line Black Friday Sale: Save Up to $3,000 on 2027 River Cruises, Plus $1,000 Off for Solo Travelers